BRPI1013844A2 - derivados de piridina-isoxazol - Google Patents
derivados de piridina-isoxazolInfo
- Publication number
- BRPI1013844A2 BRPI1013844A2 BRPI1013844A BRPI1013844A BRPI1013844A2 BR PI1013844 A2 BRPI1013844 A2 BR PI1013844A2 BR PI1013844 A BRPI1013844 A BR PI1013844A BR PI1013844 A BRPI1013844 A BR PI1013844A BR PI1013844 A2 BRPI1013844 A2 BR PI1013844A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyridine
- isoxazole derivatives
- isoxazole
- derivatives
- Prior art date
Links
- TYTSNCHBFFXCQJ-UHFFFAOYSA-N 1,2-oxazole;pyridine Chemical class C=1C=NOC=1.C1=CC=NC=C1 TYTSNCHBFFXCQJ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09159457 | 2009-05-05 | ||
| PCT/EP2010/055695 WO2010127976A1 (en) | 2009-05-05 | 2010-04-28 | Isoxazole-pyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1013844A2 true BRPI1013844A2 (pt) | 2016-04-12 |
Family
ID=42371365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1013844A BRPI1013844A2 (pt) | 2009-05-05 | 2010-04-28 | derivados de piridina-isoxazol |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8415379B2 (pt) |
| EP (1) | EP2427456B1 (pt) |
| JP (1) | JP5466292B2 (pt) |
| KR (1) | KR101367012B1 (pt) |
| CN (1) | CN102414206B (pt) |
| AU (1) | AU2010244553A1 (pt) |
| BR (1) | BRPI1013844A2 (pt) |
| CA (1) | CA2760166C (pt) |
| IL (1) | IL216007A0 (pt) |
| MX (1) | MX2011011489A (pt) |
| SG (1) | SG175867A1 (pt) |
| WO (1) | WO2010127976A1 (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2457569A1 (en) * | 2010-11-05 | 2012-05-30 | F. Hoffmann-La Roche AG | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
| PH12013500676A1 (en) | 2010-11-05 | 2013-05-06 | Hoffmann La Roche | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
| WO2013003505A1 (en) * | 2011-06-27 | 2013-01-03 | Merial Limited | Amido-pyridyl ether compounds and compositions and their use against parasites |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| AU2013283488A1 (en) | 2012-06-26 | 2015-01-15 | Saniona Aps | A phenyl triazole derivative and its use for modulating the GABAA receptor complex |
| WO2014001279A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| US9206160B2 (en) | 2012-06-26 | 2015-12-08 | Saniona Aps | Phenyl triazole derivative and its use for modulating the GABAA receptor complex |
| WO2014001278A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| WO2014001280A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| SG11201510409QA (en) | 2013-06-21 | 2016-01-28 | Zenith Epigenetics Corp | Novel bicyclic bromodomain inhibitors |
| WO2015004533A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| WO2015015318A2 (en) | 2013-07-31 | 2015-02-05 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
| US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| JP2017537946A (ja) | 2014-12-11 | 2017-12-21 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての置換複素環 |
| HK1245247A1 (zh) | 2014-12-17 | 2018-08-24 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| KR102014320B1 (ko) * | 2016-06-27 | 2019-08-26 | (주)목우연구소 | 이속사졸린 고리를 포함하는 피리딘계 화합물 및 제초제로서의 이의 용도 |
| CR20190268A (es) | 2016-12-08 | 2019-07-11 | Hoffmann La Roche | Nuevos deribados de isoxazolil éter como pam de gaba a alfa5 |
| BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| KR20240005848A (ko) | 2021-05-05 | 2024-01-12 | 유니버시티 칼리지 카디프 컨설턴츠 리미티드 | 인지 장애의 치료에 유용한 헤테로아릴 화합물 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3525205A1 (de) | 1984-09-11 | 1986-03-20 | Hoechst Ag, 6230 Frankfurt | Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols |
| GB9808663D0 (en) | 1998-04-23 | 1998-06-24 | Merck Sharp & Dohme | Therapeutic agents |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| IT1314191B1 (it) | 1999-10-18 | 2002-12-06 | Recordati Chem Pharm | Derivati isossazolcarbossamidici |
| ES2195943T3 (es) | 1999-11-12 | 2003-12-16 | Neurogen Corp | Compuestos heteroaromaticos biciclicos y triciclicos. |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| GB0108475D0 (en) | 2001-04-04 | 2001-05-23 | Merck Sharp & Dohme | New compounds |
| JP2004536104A (ja) | 2001-07-05 | 2004-12-02 | シナプティック・ファーマスーティカル・コーポレーション | Ｍｃｈ選択的アンタゴニストとしての置換されたアニリン−ピペリジン誘導体 |
| ATE381542T1 (de) | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| AU2002353844A1 (en) | 2001-11-20 | 2003-06-10 | Eli Lilly And Company | Beta 3 adrenergic agonists |
| GB0128160D0 (en) | 2001-11-23 | 2002-01-16 | Merck Sharp & Dohme | Novel compounds |
| EP1562915A1 (en) | 2002-11-22 | 2005-08-17 | SmithKline Beecham Corporation | Farnesoid x receptor agonists |
| GB0318447D0 (en) | 2003-08-05 | 2003-09-10 | Merck Sharp & Dohme | Therapeutic agents |
| AU2005250101B2 (en) | 2004-06-01 | 2011-08-25 | F. Hoffmann-La Roche Ag | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mGlu5 receptor antagonists |
| WO2005123672A2 (en) | 2004-06-14 | 2005-12-29 | Takeda San Diego, Inc. | Kinase inhibitors |
| JP4620123B2 (ja) | 2004-10-01 | 2011-01-26 | エフ．ホフマン−ラ ロシュ アーゲー | ヘキサフルオロイソプロパノール置換エーテル誘導体 |
| EP1812427A4 (en) | 2004-10-15 | 2009-10-14 | Scripps Research Inst | FATTY ACID AMIDE HYDROLASE OXADIAZOLE KETONE INHIBITORS |
| US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| WO2007009274A2 (de) | 2005-07-20 | 2007-01-25 | Prospective Concepts Ag | Pneumatisch verstellbare seitenwangen für fahrzeugsitze |
| JP2009508905A (ja) | 2005-09-19 | 2009-03-05 | エフ．ホフマン−ラ ロシュ アーゲー | ＧＡＢＡＡα５逆アゴニストとしてのイソオキサゾロ誘導体 |
| US7334639B2 (en) * | 2005-09-30 | 2008-02-26 | M-I Llc | In-situ solidification of invert emulsion fluids to form gas tight annular barrier |
| WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| ES2374165T3 (es) | 2005-12-19 | 2012-02-14 | Glaxosmithkline Llc | Agonistas del receptor x farnesoide. |
| BRPI0707427A2 (pt) | 2006-02-03 | 2011-05-03 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar dislipidemia, aterosclerose, e diabetes e complicações da mesma, para elevar os nìveis plásmicos de hdl, e para diminuir triglicerìdeos plásmicos, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo |
| JP2007230909A (ja) | 2006-03-01 | 2007-09-13 | Univ Of Tokyo | 置換イソキサゾール誘導体 |
| KR101119365B1 (ko) | 2006-05-31 | 2012-03-07 | 에프. 호프만-라 로슈 아게 | 아릴-4-에틴일-아이속사졸 유도체 |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| JP5301557B2 (ja) * | 2007-12-04 | 2013-09-25 | エフ．ホフマン−ラ ロシュ アーゲー | イソオキサゾロ−ピリジン誘導体 |
| US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| MX2010005753A (es) * | 2007-12-04 | 2010-06-15 | Hoffmann La Roche | Derivados de isoxazolo-pirazina. |
-
2010
- 2010-04-28 SG SG2011080843A patent/SG175867A1/en unknown
- 2010-04-28 CN CN201080019819.2A patent/CN102414206B/zh not_active Expired - Fee Related
- 2010-04-28 US US12/768,762 patent/US8415379B2/en not_active Expired - Fee Related
- 2010-04-28 KR KR1020117028901A patent/KR101367012B1/ko not_active Expired - Fee Related
- 2010-04-28 MX MX2011011489A patent/MX2011011489A/es active IP Right Grant
- 2010-04-28 EP EP10715271.2A patent/EP2427456B1/en active Active
- 2010-04-28 BR BRPI1013844A patent/BRPI1013844A2/pt not_active IP Right Cessation
- 2010-04-28 CA CA2760166A patent/CA2760166C/en not_active Expired - Fee Related
- 2010-04-28 WO PCT/EP2010/055695 patent/WO2010127976A1/en not_active Ceased
- 2010-04-28 JP JP2012508992A patent/JP5466292B2/ja not_active Expired - Fee Related
- 2010-04-28 AU AU2010244553A patent/AU2010244553A1/en not_active Abandoned
-
2011
- 2011-10-27 IL IL216007A patent/IL216007A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20100286132A1 (en) | 2010-11-11 |
| AU2010244553A1 (en) | 2011-12-01 |
| JP2012526071A (ja) | 2012-10-25 |
| MX2011011489A (es) | 2011-11-18 |
| WO2010127976A1 (en) | 2010-11-11 |
| CA2760166C (en) | 2017-07-18 |
| US8415379B2 (en) | 2013-04-09 |
| IL216007A0 (en) | 2012-01-31 |
| CA2760166A1 (en) | 2010-11-11 |
| EP2427456A1 (en) | 2012-03-14 |
| KR101367012B1 (ko) | 2014-03-14 |
| KR20120018349A (ko) | 2012-03-02 |
| EP2427456B1 (en) | 2020-02-05 |
| SG175867A1 (en) | 2011-12-29 |
| JP5466292B2 (ja) | 2014-04-09 |
| CN102414206A (zh) | 2012-04-11 |
| CN102414206B (zh) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1013246A2 (pt) | derivados de benzofuralina | |
| BR112012002828A2 (pt) | derivados de 5-fluorpirimidinona | |
| ECSP12011999A (es) | Derivados benzamida sustituidos | |
| BRPI1013844A2 (pt) | derivados de piridina-isoxazol | |
| EP2433940A4 (en) | SPIROIMIDAZOLONDERIVAT | |
| BR112012002662A2 (pt) | derivados de bis-benzimidazol | |
| BR112012004969A2 (pt) | derivados de bis-benzimidazol | |
| DE112010004215A5 (de) | Hydrostataktor | |
| BRPI1008774A2 (pt) | espiroamida substituída | |
| DK2397480T3 (da) | Diazepindionderivat | |
| BR112012015868A2 (pt) | derivados de imidazolidinadiona | |
| BRPI0915064A2 (pt) | derivados de qunoxalinadiona | |
| BRPI0913832A2 (pt) | derivados de pirrolopiridinilpirimidin-2-ilamina | |
| BRPI1014968A2 (pt) | subalargador | |
| BRPI1014454A2 (pt) | derivados de isoxazol-pirazol | |
| DE112010004249A5 (de) | Spindelaktor | |
| BR112012002810A2 (pt) | derivados de n1-acil-5-fluoropirimidinona | |
| DK2387580T3 (da) | Deoxyactagardinderivater | |
| BRPI0913234A2 (pt) | derivados de tiazolilpiperidina | |
| EP2401281A4 (en) | PYRIMIDINPYRIMIDOINDAZOLDERIVAT | |
| EP2409976A4 (en) | GLYCINE TRANSPORTER INHIBITOR | |
| BRPI0922652A2 (pt) | Derivados de quinazolinamida | |
| BRPI1011416A2 (pt) | derivados de antraquinova novos | |
| EP2492266A4 (en) | 5-hydroxypyrimidine-4-carboxamide | |
| BRPI1016192A2 (pt) | derivados de soxazol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2512 DE 26-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |